Last updated on January 2018

Evaluation of SPN-812ER 100 and 200mg Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial

Brief description of study

To  evaluate  the  efficacy  of  SPN-812 extended  release  (ER)  compared  to  placebo  as monotherapy for the treatment of ADHD in children (6 -11 years)

Clinical Study Identifier: TX155570

Contact Investigators or Research Sites near you

Start Over